ReachRxResearch
Home
Research
Sign Up
Clinical Practice Guideline: Tinnitus Update
Back to Research Hub
  1. Home
  2. Research Hub
  3. Clinical Practice Guideline: Tinnitus Up…

Clinical Practice Guideline: Tinnitus Update

Otolaryngology–Head and Neck Surgery·October 12
SurgeryPractice changingTinnitusClinical Practice GuidelineAnticonvulsantAntidepressantAnxiolyticBimodal NeuromodulationCochlear ImplantCognitive Behavioral TherapyDietary SupplementHearing AidIntratympanic MedicationRepetitive Transcranial Magnetic StimulationSound EnrichmentAdult

Summary

View source

What was studied

This updated clinical practice guideline evaluates and provides evidence-based recommendations for the assessment and management of persistent (≥6 months), bothersome tinnitus in adults (≥18 years), covering diagnostic evaluation, specialty referral, and therapeutic interventions.

Key findings

Strong recommendations include: distinguishing bothersome from non-bothersome tinnitus, screening for self-harm risk, and avoiding routine neuroradiologic imaging. Recommendations support audiological evaluation, hearing aid referral, cochlear implant evaluation when criteria are met, and CBT. Clinicians should not routinely offer antidepressants, anticonvulsants, anxiolytics, intratympanic medications, dietary supplements, or rTMS. Sound enrichment and bimodal neuromodulation are offered as options.

Study limitations

The guideline is based on a publisher page excerpt rather than the full text, so the strength of underlying evidence for each Key Action Statement and the detailed evidence review cannot be fully assessed. The target population is limited to adults, so findings do not apply to pediatric patients. Recommendations against several pharmacologic and neuromodulatory treatments reflect current evidence gaps rather than definitive proof of inefficacy.

Clinical implications

For adults with persistent, bothersome tinnitus, prioritize CBT as the most strongly recommended treatment, refer for hearing aid or cochlear implant evaluation when appropriate, and avoid routinely prescribing medications (antidepressants, anticonvulsants, anxiolytics), supplements, or rTMS specifically for tinnitus. Always screen for self-harm risk in this population.

Caveats

  • Only the abstract and publisher page text were available; the full guideline text was not provided, so details of individual evidence grades and supporting study data for each Key Action Statement cannot be verified
  • Prevalence estimates (10–15% of US adults; >50 million people) are cited from the guideline's own framing and may reflect self-reported tinnitus broadly, not only the persistent, bothersome subtype that is the guideline's focus
  • Recommendations against pharmacologic treatments (e.g., antidepressants, anticonvulsants) reflect a primary tinnitus indication only and do not preclude use for comorbid conditions such as depression or anxiety

Related Questions

Explore related topics

What is the evidence for cognitive behavioral therapy in treating persistent bothersome tinnitus?When should cochlear implant evaluation be considered in patients with tinnitus and hearing loss?What are the current guidelines on neuromodulation and sound therapy for chronic tinnitus management?

Publication Details

Year
2026
Journal
Otolaryngology–Head and Neck Surgery
Source
View article
Keep scrolling
More content below.
Up Next